Sugi Predict

Sugi Predict / Targets / PSMB6

PSMB6

Proteasome subunit beta type-6 · P28072 · PSMB6 on Sugi Atlas →

23,483 patent compounds predicted against PSMB6, 16,010 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL605949 SCHEMBL605949 0.54 15/20
SCHEMBL607010 SCHEMBL607010 0.56 12/20
SCHEMBL609327 SCHEMBL609327 0.55 12/20
SCHEMBL607553 SCHEMBL607553 0.54 12/20
SCHEMBL464435 SCHEMBL464435 0.54 12/20
SCHEMBL606932 SCHEMBL606932 0.53 12/20
SCHEMBL608381 SCHEMBL608381 0.53 12/20
SCHEMBL609081 SCHEMBL609081 0.52 12/20
SCHEMBL606926 SCHEMBL606926 0.52 12/20
SCHEMBL606344 SCHEMBL606344 0.51 12/20
SCHEMBL606616 SCHEMBL606616 0.51 12/20
SCHEMBL1327404 SCHEMBL1327404 0.50 12/20
SCHEMBL234139 SCHEMBL234139 0.71 11/20
Leucine Leucine (SCHEMBL1406108) 0.66 11/20
Leucine Leucine (SCHEMBL1041561) 0.63 11/20
SCHEMBL607035 SCHEMBL607035 0.61 11/20
SCHEMBL609733 SCHEMBL609733 0.60 11/20
SCHEMBL609324 SCHEMBL609324 0.60 11/20
SCHEMBL605158 SCHEMBL605158 0.59 11/20
SCHEMBL606315 SCHEMBL606315 0.59 11/20

Clinical trials — most relevant to PSMB6 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease PHASE4UNKNOWN
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer PHASE2COMPLETED
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma PHASE2COMPLETED
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors PHASE2COMPLETED
Biologic Correlative Taxotere/AC PHASE2COMPLETED
Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer PHASE2COMPLETED
A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma PHASE2WITHDRAWN
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes PHASE2UNKNOWN
Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck PHASE2COMPLETED
Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma PHASE2UNKNOWN
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study PHASE2WITHDRAWN
Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma PHASE2COMPLETED
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma PHASE1COMPLETED
Bortezomib, Fluorouracil, and Leucovorin Calcium in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma PHASE1COMPLETED
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma PHASE1COMPLETED
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors PHASE1COMPLETED
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer PHASE1COMPLETED
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS nanCOMPLETED
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS) nanUNKNOWN
Cardiovascular Complications of Carfilzomib Treatment nanUNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
The Significance of Urine UbA52 In the Diagnosis of Diabetic Nephropathy nanCOMPLETED
The Pathophysiology of Bortezomib Induced Peripheral Neuropathy nanUNKNOWN
Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT) nanUNKNOWN
Ultrasound Enthesitis Response in Psoriatic Arthritis nanCOMPLETED
Establishment of Human Cellular Disease Models for Wilson Disease nanCOMPLETED
Cholesterol and Statin in Healthy Adults nanCOMPLETED
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PSMB6 binder may also engage these)

ProteinNameSimilarity
Q3MHN0 — 1.000 Q3MHN0 →
P28073 — 1.000 P28073 →
Q60692 — 1.000 Q60692 →
O35524 — 0.994 O35524 →
O35523 — 0.994 O35523 →
O35521 — 0.993 O35521 →
P28077 — 0.992 P28077 →
Q3SZC2 — 0.992 Q3SZC2 →
PSMB9 Proteasome subunit beta type-9 0.992 landscape →
P28076 — 0.992 P28076 →
Q8LD27 — 0.992 Q8LD27 →
O35522 — 0.991 O35522 →
P93395 — 0.987 P93395 →
Q8UW64 — 0.986 Q8UW64 →
Q9DD33 — 0.986 Q9DD33 →
P70195 — 0.985 P70195 →
P38624 — 0.985 P38624 →
A7KE01 — 0.985 A7KE01 →
A1XQU1 — 0.984 A1XQU1 →
A7KII6 — 0.984 A7KII6 →
P28064 — 0.984 P28064 →
PSMB7 Proteasome subunit beta type-7 0.984 landscape →
Q9PT26 — 0.982 Q9PT26 →
P28075 — 0.982 P28075 →
Q55GJ6 — 0.981 Q55GJ6 →
O55234 — 0.981 O55234 →
Q8SR11 — 0.981 Q8SR11 →
P28063 — 0.981 P28063 →
Q3T112 — 0.980 Q3T112 →
O43063 — 0.980 O43063 →